Target Xpoze Therapeutics
Making hidden cancer cells targetable
An AI-enabled precision-oncology company developing target-restoration therapeutics for hidden, therapy-resistant cancer cells that escape current targeted treatments.
Why traditional therapies fail
More than 90% of solid-tumor mortality is driven by metastasis and disease relapse, both originating from minimal residual disease: small populations of therapy-resistant cancer cells that survive treatment by hiding their therapeutic targets from the cell surface. Even with today's most advanced HER2-targeted antibody-drug conjugates, roughly half of HER2-positive breast cancer patients still relapse within five years.
Programmable computational oncology
Target Xpoze restores therapeutic visibility, allowing existing FDA-approved therapies to reach cancer cells they currently miss. Mechanism and molecular composition are proprietary and disclosed only under NDA.
Proof Points
Validated Foundation
External validation — Supported by competitive, non-dilutive research funding and independent peer review.
In vitro validation — Demonstrated restoration of therapeutic target accessibility on resistant cancer cells in laboratory models.
In vivo validation — Preclinical models show delayed tumor progression when the approach is applied.
Patient-derived validation — Confirmed in samples from patients with treatment-resistant disease.
In silico validation — AI-guided computational design supports candidate identification and prioritization.
Pioneering computational oncology
Dr. Heda Hosseini
Dr. Amir Feizi
Biomedical scientist with expertise in cancer biology and precision oncology. Co-founder and CEO/CSO of Target Xpoze Therapeutics.
Computational biologist and AI engineer specialising in multi-omics integration and machine learning for drug target discovery. Co-founder and CTO.
Partnering and investor inquiries
We welcome inquiries from investors, accelerator programs, healthcare partners, and pharmaceutical business-development teams. Confidential scientific and technical materials are available only under NDA.